Clinical trials: Diabetes Type II
Diabetes Mellitus, Type 2
SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes
Despite the development of novel treatments, cardiovascular disease (CVD) remains the leading cause of death and disability. It has been observed in clinical practice, that the use of novel glycemia-lowering therapies with…
- Trial name
- NCT05256706
- Testing
- SomaSignal Informed Medical Management SSCVD, Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 143 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 2
A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)
The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET®) from endocrinologists, diabetologists, internists, and general practitioners.
- Trial name
- NCT01357148
- Testing
- Sitagliptin Phosphate/Metformin HCl (JANUMET®)
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Coronary Artery Disease
Aspirin Dosing in Diabetic Patients
Since diabetic platelets are characterized by an enhanced turnover rate, it may be hypothesized that an increase in the frequency, rather than the dose, of drug administration may be a more effective strategy to inhibit platelet…
- Trial name
- NCT01201785
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Diabetic Nephropathy
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo
- Trial name
- NCT03436693
- Testing
- Canagliflozin
- Where
- 26 sites in Japan
- Volunteers
- 308 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
This trial was conducted in Europe and North America. The aim of this clinical trial was to compare NN1250 (insulin degludec (IDeg)), a soluble insulin basal analogue (SIBA), with insulin glargine (IGlar), as add-on to subject's…
- Trial name
- BEGIN™ (NCT01076647)
- Testing
- insulin degludec, insulin glargine
- Where
- 105 sites in United States, Bulgaria and 5 more
- Volunteers
- 467 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
This study will examine the safety and efficacy of the addition of omarigliptin in Japanese participants with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent…
- Trial name
- NCT01697592
- Testing
- Omarigliptin
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type II, Fatty Liver
Study of INT-747 in Patients With Diabetes and Presumed NAFLD
The primary objectives of this study are to assess, in patients with Type 2 diabetes mellitus (DM) and presumed nonalcoholic fatty liver disease (NAFLD), the following: The safety and tolerability of multiple doses of INT 747…
- Trial name
- NCT00501592
- Testing
- INT-747
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Intercept Pharmaceuticals
Diabetes Mellitus, Type 2
Diabetes Homelessness Medication Support Program in Spanish
This single-arm trial of the Diabetes Homeless Medication Support intervention for Spanish-speaking people (n=12) will test the perception and feasibility of anticipated study procedures.
- Trial name
- DH-Spanish (NCT05819749)
- Testing
- Diabetes Homelessness Medication Support Program in Spanish
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Hennepin Healthcare Research Institute
Diabetes Mellitus, Type 2
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as enteric…
- Trial name
- RITE (NCT02008942)
- Testing
- PL2200 Aspirin Capsules, Enteric-coated aspirin caplets
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- PLx Pharma
Prediabetes
Interdisciplinary and Family Intervention to Prevent Type 2 Diabetes
The purpose of the study is to evaluate the effect of a family and interdisciplinary approach on individual and family insulin resistance and insulin secretion in patients with prediabetes.
- Trial name
- CARE-in-DEEP (NCT02635646)
- Testing
- Family and interdisciplinary approach, individual approach
- Where
- Mexico
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Universidad de Guanajuato
Type2 Diabetes
The Effect of Hypoxia on Type 2 Diabetes and Weight Loss
The number of people with type 2 diabetes mellitus (T2DM) continuing to rise, this pandemic is expected to reach 700 million people by 2045.
- Trial name
- NCT05147116
- Testing
- Sleeping in a tent
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- University of Portsmouth
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus sitagliptin 100 mg once-daily on glycaemic control…
- Trial name
- SUSTAIN (NCT03061214)
- Testing
- Semaglutide 0.5 mg, Semaglutide 1.0 mg, Sitagliptin
- Where
- 67 sites in Brazil, China and 5 more
- Volunteers
- 868 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes
The purpose of this study is to compare the effects of exenatide once weekly (QW) and insulin detemir with respect to glycemic control, body weight, lipids, safety, tolerability, and patient reported outcomes.
- Trial name
- NCT01003184
- Testing
- exenatide once weekly, insulin detemir
- Where
- 34 sites in Ireland, United Kingdom
- Volunteers
- 222 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00642616
- Testing
- Technosphere® Insulin, Usual Care
- Where
- 21 sites in United States, Russia and 1 more
- Volunteers
- 34 people
- Sponsor
- Mannkind Corporation
Aging, Diabetes Mellitus, Type 2
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management.
- Conditions
- Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
- Trial name
- NCT05786521
- Testing
- Semaglutide Injectable Product, Lifestyle Counseling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia and North America. The aim of this trial is to compare two insulin degludec (NN1250, SIBA) formulations with each other and with insulin glargine, all in combination with metformin in…
- Trial name
- NCT00611884
- Testing
- insulin glargine, insulin degludec, metformin
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
- Trial name
- NCT04295005
- Testing
- Empagliflozin, DPP-4i, GLP-1-RA
- Where
- Germany
- Volunteers
- 24,500 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus
To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once daily oral doses of empagliflozin in Japanese patients with type 1 diabetes mellitus as adjunctive therapy to insulin.
- Trial name
- NCT02702011
- Testing
- empagliflozin medium dose, empagliflozin low dose, empagliflozin high dose
- Where
- 4 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH…
- Trial name
- NCT00795600
- Testing
- insulin detemir, insulin NPH
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2…
- Trial name
- NCT00881530
- Testing
- BI 10773, Metformin, Sitagliptin
- Where
- 137 sites in United States, Austria and 19 more
- Volunteers
- 660 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.